Disease-Modifying Therapies for Alzheimer's Disease

Introduction

Disease Modifying Therapies For Alzheimer'S Disease is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Amyloid-Targeting Therapies

Monoclonal Antibodies (Approved)

Lecanemab (Leqembi)

• Mechanism: Humanized IgG1 that binds soluble [Aβ](/proteins/amyloid-beta) protofibrils
• Approval: FDA full approval January 2023
• CLARITY-AD Trial: 27% slowing of cognitive decline at 18 months
• Dose: 10 mg/kg IV every 2 weeks
• ARIA risk: ~12.6% (ARIA-E), 17.3% (ARIA-H)
• Amyloid removal: Significant plaque reduction at 18 months

Donanemab (Kisunla)

• Mechanism: N-terminal pyroglutamate [Aβ](/proteins/amyloid-beta) specific antibody
• Approval: FDA approval July 2024
• TRAILBLAZER-ALZ 2: 35% slowing of decline in low/medium [tau](/proteins/tau) population
• Dose: 350 mg IV every 4 weeks after titration
• Limited dosing: Can stop at amyloid clearance
• ARIA risk: 24% (any ARIA)

Introduction

Disease Modifying Therapies For Alzheimer'S Disease is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Amyloid-Targeting Therapies

Monoclonal Antibodies (Approved)

Lecanemab (Leqembi)

• Mechanism: Humanized IgG1 that binds soluble [Aβ](/proteins/amyloid-beta) protofibrils
• Approval: FDA full approval January 2023
• CLARITY-AD Trial: 27% slowing of cognitive decline at 18 months
• Dose: 10 mg/kg IV every 2 weeks
• ARIA risk: ~12.6% (ARIA-E), 17.3% (ARIA-H)
• Amyloid removal: Significant plaque reduction at 18 months

Donanemab (Kisunla)

• Mechanism: N-terminal pyroglutamate [Aβ](/proteins/amyloid-beta) specific antibody
• Approval: FDA approval July 2024
• TRAILBLAZER-ALZ 2: 35% slowing of decline in low/medium [tau](/proteins/tau) population
• Dose: 350 mg IV every 4 weeks after titration
• Limited dosing: Can stop at amyloid clearance
• ARIA risk: 24% (any ARIA)

Aducanumab (Aduhelm)

• Mechanism: Human IgG1 against Aβ aggregates
• Approval: Accelerated approval 2021 (controversial)
• ENGAGE/EMERGE trials: Mixed results, high dose showed benefit
• Discontinued: Manufacturer discontinued 2024
• ARIA risk: 35% (ARIA-E)

Monoclonal Antibodies (Investigational)

Crenezumab (RG6102)

• Mechanism: Anti-Aβ protofibril antibody
• Phase III: CREAD trials (negative)
• API-AD trial: Ongoing in autosomal dominant AD

Gantenerumab (RG1450)

• Mechanism: Fully human IgG1
• Phase III: Graduate trials (negative)
• GRADUATE 1/2: Did not meet primary endpoint

Solanezumab (LY2062430)

• Mechanism: Anti-soluble Aβ mid-domain
• Phase III: EXPEDITION trials (negative)
• DIAN-TU: Ongoing in preclinical AD

BACE Inhibitors (Discontinued)

Verubecestat (MK-8931)

• Mechanism: [BACE1](/entities/bace1)/2 inhibitor
• Phase III: Stopped for cognitive worsening
• EPOCH: Negative in mild-to-moderate AD

Lanabecestat (AZD3293)

• Mechanism: BACE inhibitor
• Phase III: Stopped for liver toxicity
• AMARANTH/DAYLIGHT: Negative

Elenbecestat (E2609)

• Mechanism: BACE inhibitor
• Phase III: Stopped for cognitive worsening
• MISSION AD: Negative

Tau-Targeting Therapies

Immunotherapies

Tilavonemab (ABBV-8E12)

• Mechanism: Anti-tau antibody targeting N-terminus
• Phase II: Negative in PSP (LIGUSTRING)
• TAURIELD: Ongoing in AD

Semorinemab (RG6100)

• Mechanism: Anti-tau antibody
• Phase II: Negative in prodromal/mild AD (LAURIET)
• Phase II: Negative in moderate AD (AMBITION)

Gosuranemab (BMS-986446)

• Mechanism: Anti-tau N-terminal antibody
• Phase II: Negative in AD (TANGO)

JNJ-63733657

• Mechanism: Anti-tau antibody
• Phase II: Ongoing in AD

Small Molecule Inhibitors

Methylthioninium Chloride (MTC)

• Mechanism: [Tau](/proteins/tau) aggregation inhibitor
• Phase III: Negative in mild AD (ROCKET)
• Formulation issues: Bioavailability

Davunetide (NAP)

• Mechanism: Microtubule stabilizer
• Phase III: Negative in PSP (ALLATOR)

Anti-Inflammatory Approaches

Neuroinflammation Modulators

Masitinib

• Mechanism: Tyrosine kinase inhibitor
• Phase III: Positive signal in mild-to-moderate AD
• AB10015: 60% slowing in cognitive decline

Sargramostim (GM-CSF)

• Mechanism: Myeloid stimulation
• Phase II: Positive signal in AD
• Immunity and AD study

Metabolic and Synaptic Support

Synaptic Plasticity Enhancers

Levetiracetam

• Mechanism: SV2A modulator
• Phase II: Reduced hippocampal hyperactivity
• 、改善了轻度认知障碍患者的记忆力

Ampalorex (BMS-986204)

• Mechanism: Negative allosteric modulator of muscarinic M1
• Phase II: Negative in mild AD

Future Directions

Combination Approaches

• Amyloid removal + tau targeting
• Amyloid + neuroinflammation
• Multi-target therapies

Prevention Trials

• [Dominantly Inherited Alzheimer Network](/entities/dian-study) Trials Unit (DIAN-TU)
• Alzheimer's Prevention Initiative (API)
• A4 Study (Anti-Amyloid in Asymptomatic AD)

Novel Targets

• Synaptic plasticity and function
• Mitochondrial dysfunction
• Neurovascular unit
• [Microbiome](/entities/microbiome)-[gut-brain axis](/entities/gut-brain-axis)

Clinical Considerations

Patient Selection

• Biomarker confirmation (amyloid PET, CSF)
• Disease stage
• Comorbidities
• [APOE](/proteins/apoe-protein) status

Monitoring

• ARIA surveillance (for monoclonal antibodies)
• Cognitive assessments
• Functional measures
• Biomarker changes

See Also

• [Lecanemab](/therapeutics/lecanemab)
• [Donanemab](/therapeutics/donanemab)
• [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)
• [Amyloid Cascade](/mechanisms/amyloid-cascade-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

Background

The study of Disease Modifying Therapies For Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

^[1] van Dyck CH, et al. N Engl J Med. 2023;388(1):9-21. PMID: 36459553(https://pubmed.ncbi.nlm.nih.gov/36459553/)

^[2] Sims JR, et al. JAMA. 2023;329(13):1083-1097. PMID: 36961827(https://pubmed.ncbi.nlm.nih.gov/36961827/)

^[3] Swaddiwudhipong N, et al. Nat Rev Neurol. 2023;19(12):715-728. PMID: 37993563(https://pubmed.ncbi.nlm.nih.gov/37993563/)

^[4] Liu KY, et al. Nat Rev Drug Discov. 2023;22(10):779-799. PMID: 37758986(https://pubmed.ncbi.nlm.nih.gov/37758986/)

^[5] Mintun MA, et al. N Engl J Med. 2021;384(18):1691-1704. PMID: 33951237(https://pubmed.ncbi.nlm.nih.gov/33951237/)

^[6] Herring WL, et al. J Prev Alzheimers Dis. 2024;11(1):9-18. PMID: 38218724(https://pubmed.ncbi.nlm.nih.gov/38218724/)

^[7] Karran E, et al. Nat Rev Drug Discov. 2024;23(2):87-108. PMID: 38129473(https://pubmed.ncbi.nlm.nih.gov/38129473/)

^[8] Hampel H, et al. Mol Psychiatry. 2024;29(2):427-445. PMID: 38148394(https://pubmed.ncbi.nlm.nih.gov/38148394/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
• [Prefrontal sensory gating circuit restoration via PV interneuron enhancement](/hypothesis/h-62f9fc90) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: PVALB
• [Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: TREM2
• [GFAP-Positive Reactive Astrocyte Subtype Delineation](/hypothesis/h-seaad-56fa6428) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: GFAP
• [Excitatory Neuron Vulnerability via SLC17A7 Downregulation](/hypothesis/h-seaad-7f15df4c) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: SLC17A7

Related Analyses:

• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) &#x1f504;
• [Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;